BPC-157 is a synthetic peptide derived from a protein found in human gastric juice, known for its wide range of potential therapeutic benefits.
 It supports tissue repair and regeneration across multiple systems, including muscles, tendons, ligaments, and bones, by stimulating collagen synthesis and enhancing angiogenesis—the formation of new blood vessels—which improves nutrient and oxygen delivery to damaged tissues.
 This mechanism accelerates healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle strains.
The peptide exhibits strong anti-inflammatory properties by modulating inflammatory pathways, reducing levels of pro-inflammatory cytokines, and downregulating genes like Nfkb and Nos2 that contribute to excessive inflammation.
 This effect helps alleviate pain and swelling associated with conditions like arthritis, bursitis, tendinitis, and inflammatory bowel disease.
BPC-157 significantly improves gut health by protecting and repairing the gastrointestinal lining, strengthening the mucosal barrier, and preventing leaky gut syndrome.
 It has shown promise in managing digestive disorders such as ulcers, Crohn’s disease, irritable bowel syndrome (IBS), and ulcerative colitis.
 Its ability to maintain gut integrity is linked to its stability in gastric juice, remaining intact for over 24 hours when taken orally.
Neuroprotective effects have been observed in animal models, where BPC-157 demonstrated benefits in spinal cord injury, traumatic brain injury, peripheral nerve transection, and concussive trauma.
 It supports recovery from neurological damage by promoting nerve regeneration, reducing neuronal damage, and improving motor function and coordination.
 Additionally, it has shown potential in mitigating symptoms related to dopamine and nitric oxide system disturbances, including those associated with schizophrenia-like symptoms and catalepsy in animal models.
The peptide also enhances overall recovery and performance, making it popular among athletes and individuals recovering from injuries.
 It promotes muscle strength, counters muscle weakness, and aids in functional recovery after neuromuscular injuries.
 Furthermore, BPC-157 has been shown to protect organs such as the liver, pancreas, and heart from damage and supports vascular function by activating the VEGFR2 pathway and increasing nitric oxide production, which improves blood flow.
Despite its promising preclinical results, BPC-157 is not approved by any drug regulatory agency for human use, and clinical data in humans remain limited.
 A 2025 pilot study involving intravenous administration in two adults reported no adverse effects on major organ systems, suggesting it may be well-tolerated.
 However, concerns exist regarding potential cancer promotion due to its angiogenic properties, and it is banned by the World Anti-Doping Agency (WADA) under the S0 category of non-exempt substances.
 Due to unregulated manufacturing and lack of clinical safety data, health authorities caution against its use without medical supervision.